- Previous Close
10.10 - Open
10.10 - Bid 10.00 x --
- Ask 10.05 x --
- Day's Range
10.05 - 10.15 - 52 Week Range
4.12 - 10.15 - Volume
471 - Avg. Volume
24,978 - Market Cap (intraday)
85.425M - Beta (5Y Monthly) 1.25
- PE Ratio (TTM)
-- - EPS (TTM)
-0.83 - Earnings Date Mar 26, 2025 - Mar 31, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
13.25
Apontis Pharma AG engages in the marketing and sale of medical drugs for indication fields of internal medicine in Germany. It offers single pills and other pharmaceutical products with a focus on cardiovascular diseases, such as hypertension, hyperlipidemia, and secondary prophylaxis, as well as respiratory diseases and diabetes. The company was founded in 1946 and is based in Monheim am Rhein, Germany. As of November 21, 2024, Apontis Pharma AG operates as a subsidiary of Zentiva AG.
apontis-pharma.de177
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: APPH.DE
View MorePerformance Overview: APPH.DE
Trailing total returns as of 12/27/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: APPH.DE
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: APPH.DE
View MoreValuation Measures
Market Cap
82.62M
Enterprise Value
66.46M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.10
Price/Book (mrq)
2.76
Enterprise Value/Revenue
1.64
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-17.42%
Return on Assets (ttm)
-4.51%
Return on Equity (ttm)
-20.51%
Revenue (ttm)
40.63M
Net Income Avi to Common (ttm)
-7.08M
Diluted EPS (ttm)
-0.83
Balance Sheet and Cash Flow
Total Cash (mrq)
16.16M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-2.73M